Found: 15
Select item for more details and to access through your institution.
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01033-7
- By:
- Publication type:
- Article
FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03010-7
- By:
- Publication type:
- Article
8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia.
- Published in:
- Journal of Cellular Physiology, 2019, v. 234, n. 9, p. 16295, doi. 10.1002/jcp.28294
- By:
- Publication type:
- Article
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. E32, doi. 10.1002/ajh.27161
- By:
- Publication type:
- Article
Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-48167-4
- By:
- Publication type:
- Article
Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation.
- Published in:
- Cellular & Molecular Life Sciences, 2021, v. 78, n. 23, p. 7851, doi. 10.1007/s00018-021-03977-6
- By:
- Publication type:
- Article
MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S349, doi. 10.1016/S2152-2650(21)01810-3
- By:
- Publication type:
- Article
MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S350, doi. 10.1016/S2152-2650(21)01811-5
- By:
- Publication type:
- Article
Poster: MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01448-8
- By:
- Publication type:
- Article
Poster: MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01447-6
- By:
- Publication type:
- Article
Somatic MED12 Mutations in Prostate Cancer and Uterine Leiomyomas Promote Tumorigenesis Through Distinct Mechanisms.
- Published in:
- Prostate, 2016, v. 76, n. 1, p. 22, doi. 10.1002/pros.23092
- By:
- Publication type:
- Article
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
- Published in:
- Nature, 2015, v. 519, n. 7541, p. 102, doi. 10.1038/nature14119
- By:
- Publication type:
- Article
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.
- Published in:
- Scientific Reports, 2014, p. 1, doi. 10.1038/srep05193
- By:
- Publication type:
- Article
Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry.
- Published in:
- Human Mutation, 2017, v. 38, n. 3, p. 269, doi. 10.1002/humu.23157
- By:
- Publication type:
- Article
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-52980-5
- By:
- Publication type:
- Article